Literature DB >> 17103087

How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency.

Ajay Bhatia1, Richard E Kast.   

Abstract

Neuraminidase (NA) is an enzyme coded for by the genome of influenza critical for its pathogenicity and survival. Three currently accepted roles for this NA in promoting influenza virulence are: 1. NA cleaves newly formed virus particles from the host cell membrane. Without NA, newly formed virus would remain attached to the cell within which it was produced. 2. NA prevents newly released virus particles from aggregating to each other, preventing clumping that would reduce dissemination. 3. NA promotes viral penetration of sialic acid-rich mucin that bathes and protects respiratory epithelium through which the virus must spread and replicate. We outline here previous research evidence of two further, albeit hypothetical, functions of NA that together could cause disruption the mucosa-IgA axis, creating localized partial immunosuppressed state, enhancing both influenza infection itself and secondary bacterial pneumonia: 4. IgA provides primary immunoglobulin defense of mucosal surfaces. The hinge region of IgA is normally sialylated. IgA denuded of sialic acid is recognized, bound, and cleared by hepatic asialoglycoprotein receptor (ASGPR). Thus, IgA exposed to free NA would be so denuded and have increased hepatic clearance. 5. NA removes sialic acid moieties from mucosa-residing gamma/delta T cells or IgA producing B cells. Previous work indicates desialylation of these lymphocytes' outer cell membrane results in altered homing, to bone marrow, away from mucosa. Currently marketed NA inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) are FDA approved in USA for influenza prophylaxis and treatment. These NA inhibitors lower incidence of secondary bacterial infection in cases where an influenza infection occurs despite their use. Moreover, they are ameliorative in patients with secondary bacterial infections treated with antibiotics, a benefit that surpasses the treatment of antibiotics alone. We interpret these last two points as indicating our ascription of localized immunosuppression to influenza's NA could be correct and lead to new treatments of infections generally.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103087      PMCID: PMC6275963          DOI: 10.2478/s11658-006-0055-x

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  36 in total

Review 1.  Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes.

Authors:  Reiji Kannagi
Journal:  Curr Opin Struct Biol       Date:  2002-10       Impact factor: 6.809

2.  Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy.

Authors:  Eric Lewin Altschuler; Ajay Bhatia; Richard E Kast
Journal:  Kidney Int       Date:  2005-12       Impact factor: 10.612

3.  Influenza virus neuraminidase contributes to secondary bacterial pneumonia.

Authors:  Ville T Peltola; K Gopal Murti; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2005-06-08       Impact factor: 5.226

Review 4.  A novel approach to antiviral therapy for influenza.

Authors:  P M Colman
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

5.  A theory of lymphocyte blast transformation (LBT) and malignant change based on proteolytic cleavage of trigger peptide: the detendomer.

Authors:  R E Kast
Journal:  Oncology       Date:  1974       Impact factor: 2.935

6.  Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

Authors:  Jonathan A McCullers; Kimberly C Bartmess
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

7.  Molecular aspects of immunoglobulin A1 degradation by oral streptococci.

Authors:  J Reinholdt; M Tomana; S B Mortensen; M Kilian
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

9.  Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.

Authors:  Jonathan A McCullers
Journal:  J Infect Dis       Date:  2004-06-30       Impact factor: 5.226

Review 10.  The treatment of influenza with antiviral drugs.

Authors:  Grant Stiver
Journal:  CMAJ       Date:  2003-01-07       Impact factor: 8.262

View more
  8 in total

Review 1.  Postinfluenza bacterial pneumonia: host defenses gone awry.

Authors:  Megan N Ballinger; Theodore J Standiford
Journal:  J Interferon Cytokine Res       Date:  2010-09       Impact factor: 2.607

Review 2.  The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-04       Impact factor: 3.402

3.  Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Authors:  Kanyarat Ruangrung; Ornpreya Suptawiwat; Kittipong Maneechotesuwan; Chompunuch Boonarkart; Warunya Chakritbudsabong; Jirawatna Assawabhumi; Parvapan Bhattarakosol; Mongkol Uiprasertkul; Pilaipan Puthavathana; Witthawat Wiriyarat; Anan Jongkaewwattana; Prasert Auewarakul
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

4.  Influenza A virus neuraminidase protein enhances cell survival through interaction with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) protein.

Authors:  Pratibha Gaur; Priya Ranjan; Shipra Sharma; Jenish R Patel; J Bradford Bowzard; Shah K Rahman; Rashmi Kumari; Shivaprakash Gangappa; Jacqueline M Katz; Nancy J Cox; Renu B Lal; Suryaprakash Sambhara; Sunil K Lal
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

Review 5.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

6.  Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation.

Authors:  Pablo Granados-Durán; María Dolores López-Ávalos; Manuel Cifuentes; Margarita Pérez-Martín; María Del Mar Fernández-Arjona; Timothy R Hughes; Krista Johnson; B Paul Morgan; Pedro Fernández-Llebrez; Jesús M Grondona
Journal:  Front Neurol       Date:  2017-03-07       Impact factor: 4.003

Review 7.  MicroRNA let-7 and viral infections: focus on mechanisms of action.

Authors:  Arash Letafati; Sajad Najafi; Mehran Mottahedi; Mohammad Karimzadeh; Ali Shahini; Setareh Garousi; Mohammad Abbasi-Kolli; Javid Sadri Nahand; Seyed Saeed Tamehri Zadeh; Michael R Hamblin; Neda Rahimian; Mohammad Taghizadieh; Hamed Mirzaei
Journal:  Cell Mol Biol Lett       Date:  2022-02-14       Impact factor: 5.787

8.  The mechanisms of delayed onset type adverse reactions to oseltamivir.

Authors:  Rokuro Hama
Journal:  Infect Dis (Lond)       Date:  2016-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.